Evaxion A/S, a clinical-stage TechBio company, has announced that it will present new biomarker data from its phase 2 trial of the personalized cancer vaccine EVX-01 at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting. This event, taking place in Phoenix, Arizona, from November 4-8, 2026, is significant as it showcases Evaxion's advancements in immunotherapy and its AI-Immunology™ platform.

The presentation will include an analysis of the systemic immunomodulatory effects of EVX-01, particularly when combined with pembrolizumab, a therapy developed by Merck. This data is crucial as it provides insights into how the vaccine interacts with the immune system, which is vital for developing effective cancer treatments.

Background

Evaxion A/S specializes in developing innovative immunotherapies using its proprietary AI-Immunology™ platform. The company is classified under the SIC code 2836, which pertains to Biological Products, (No Diagnostic Substances). It is listed on the Nasdaq under the ticker EVAX. Recent filings show that Evaxion has been active in reporting its progress, with multiple submissions leading up to this announcement.

What the Filing Says

The filing dated November 3, 2026, reveals that Evaxion will present data from its phase 2 trial, indicating that the vaccine has shown promising results. The press release states, “The new data includes analysis of broad systemic immunomodulatory effects of EVX-01 plus pembrolizumab beyond vaccine-specific T-cell responses.” This suggests that the vaccine may have a more extensive impact on the immune system than previously understood.

Impact

This announcement may significantly affect patients with advanced melanoma and the broader oncology community. By presenting at a major conference, Evaxion is positioning itself as a key player in the development of personalized cancer vaccines. The results could influence treatment protocols and lead to further research and development in the field.

What's Next

The filing does not specify what happens next after the presentation. However, the outcomes of the SITC meeting could lead to further studies or partnerships as Evaxion seeks to advance its clinical programs.